- Clinical Interests
- Memory disorders
- Olfactory disorders
- Amyotrophic lateral sclerosis (ALS)
- Medical Education
- MD, Harvard Medical School
- PhD, Harvard University
- Residency, Brigham and Women's Hospital|Residency, Massachusetts General Hospital
- Fellowship, Neurological Institute of New York
- Board Certifications
- Boston: Massachusetts General Hospital
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Mark W. Albers is a neurologist specializing in memory and olfactory disorders. He earned a PhD in organic chemistry from Harvard University, working in the laboratory of Stuart Schreiber, and an MD degree from the H.S.T. program of Harvard Medical School and M.I.T. He was an internal medicine resident for two years at Massachusetts General Hospital and then trained in neurology at Mass General, and Brigham and Women's Hospital, where he was one of the first chief residents for the Partners neurology residency program. Following clinical training, he resumed basic research studies in the laboratory of Richard Axel and practiced behavioral neurology in the Memory Disorders Center at the Neurological Institute, affiliated with Columbia University. Following this training, he returned to Mass General where he sees outpatients in the Memory Disorders Unit and attends on the inpatient neurologic wards. His clinical research is focused on devising sensitive probes of olfactory function as a possible biomarker for early neurodegenerative disease and directly converting olfactory neuronal precursor cells from the nose into brain neurons to develop cell-based models of neurologic disease. He is a member of the Translational Neuroscience committee of the American Academy of Neurology.
- Research Summary
The goal of the research in the Albers lab is to elucidate the pathogenic actions and physiological functions of genes implicated in neurodegenerative disease.
Read more about the Albers Lab.
Mark Albers, MD, PhD, from Massachusetts General Hospital, discovered a new mechanism that damages nerve cells and triggers an inflammatory response in people with ALS and those with Alzheimer’s disease (AD).
A non-invasive protocol developed by Massachusetts General Hospital investigators that tests the ability to recognize, remember and distinguish between odors was able to identify older individuals who – according to genetic, imaging and more detailed memory tests – were at increased risk of Alzheimer’s disease.
Mark Albers, MD, PhD, of the Department of Neurology, was named the first incumbent of the Frank Wilkens, Jr. and Family Endowed Chair in Alzheimer’s Disease Research.
15 Parkman Street
Boston, MA 02114-3117